Skip to content

Medical emergency? What to do

Predicting cancer prognosis

3-RXPublished August 27, 20093 min read

Key points

  • Soheil Dadras at the Stanford University Medical Center have developed a novel methodology to extract microRNAs from cancer tissues.
  • Dadras and colleagues optimized a new protocol for extracting miRNAs from formalin-fixed paraffin-embedded tissues.
  • Ma Z, Lui W-O, Fire A, Dadras SS: Profiling and discovery of novel miRNAs from formalin-fixed paraffin-embedded melanoma and nodal specimens.
  • For press copies of the articles, please contact Dr.

Researchers led by Dr. Soheil Dadras at the Stanford University Medical Center have developed a novel methodology to extract microRNAs from cancer tissues. The related report by Ma et al, "Profiling and discovery of novel miRNAs from formalin-fixed paraffin-embedded melanoma and nodal specimens," appears in the September 2009 issue of the Journal of Molecular Diagnostics.

Cancer tissues from patients are often stored by a method that involves formalin fixation and paraffin embedding to retain morphological definition for identification; however, this method frequently prevents further molecular analysis of the tissue because of mRNA degradation. Even so, these tissues contain high numbers of microRNAs (miRNAs), which are short enough (~22 nucleotides) to not be broken down during the fixation process.

In this study, Dr. Dadras and colleagues optimized a new protocol for extracting miRNAs from formalin-fixed paraffin-embedded tissues. Using their new procedure, they identified 17 new and 53 known miRNAs from normal skin, melanoma, and sentinel lymph nodes. These miRNAs were well-preserved in a 10-year-old specimen.

This new protocol, therefore, will allow for the identification of novel miRNAs that may differ in cancerous and healthy tissue, even from long-preserved tissue, leading to better predictions of disease prognosis and treatment response.

Ma et al suggest that their "cloning strategy has the advantage of not only discovering novel and known miRNA sequence identity but also providing an estimate of relative expression level. … [This methodology may provide] a more robust strategy to obtain an accurate expression profile for novel and/or previously characterized small RNAs from clinically defined [formalin-fixed paraffin-embedded] tumor specimens, thereby facilitating the discovery of 'oncomirs' as biomarkers."

###

Ma Z, Lui W-O, Fire A, Dadras SS: Profiling and discovery of novel miRNAs from formalin-fixed paraffin-embedded melanoma and nodal specimens. J Mol Diagn 2009, 420-429

This work was supported in part by 2007 Dermatology Foundation Dermatopathology Research Grant and the department of Pathology research funds at Stanford University Medical Center.

For press copies of the articles, please contact Dr. Angela Colmone at 301-634-7953 or acolmone@asip.org.

The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology, co-published by the American Society for Investigative Pathology, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome for review articles that contain: novel discoveries or clinicopathologic correlations including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description or polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition.

Contact: Angela Colmone
acolmone@asip.org
301-634-7953
American Journal of Pathology

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underCancer

Keep reading

Brain

Italy court ruling links mobile phone use to tumor

Italy's supreme court has upheld a ruling that said there was a link between a business executive's brain tumor and his heavy mobile phone usage, potentially opening the door to further legal claims. The court's…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.